<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MANNITOL <img border="0" src="../images/pr.gif"/></span><br/>(man'i-tole)<br/><span class="topboxtradename">Osmitrol<br/></span><b>Classifications:</b> <span class="classification">electrolytic and water balance agent</span>; <span class="classification">osmotic diuretic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5%, 10%, 15%, 20%, 25% injection</p>
<h1><a name="action">Actions</a></h1>
<p>In large doses, increases rate of electrolyte excretion by the kidney, particularly sodium, chloride, and potassium.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces diuresis by raising osmotic pressure of glomerular filtrate, thereby inhibiting tubular reabsorption of water and
         solutes. Reduces elevated intraocular and cerebrospinal pressures by increasing plasma osmolality, thus inducing diffusion
         of water from these fluids back into plasma and extravascular space.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To promote diuresis in prevention and treatment of oliguric phase of acute kidney failure following cardiovascular surgery,
         severe traumatic injury, surgery in presence of severe jaundice, hemolytic transfusion reaction. Also used to reduce elevated
         intraocular (IOP) and intracranial pressure (ICP), to measure glomerular filtration rate (GFR), to promote excretion of toxic
         substances, to relieve symptoms of pulmonary edema, and as irrigating solution in transurethral prostatic reaction to minimize
         hemolytic effects of water. Commercially available in combination with sorbitol for urogenital irrigation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Anuria; marked pulmonary congestion or edema; severe CHF; metabolic edema; organic CNS disease, intracranial bleeding; shock,
         severe dehydration, history of allergy; pregnancy (category C), lactation; concomitantly with blood.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Kidney Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Test Dose</span> 0.2 g/kg or 12.5 g as a 1520% solution over 35 min <span class="rdroute">Positive Response</span> 3050 mL of urine over next 23 h, may repeat test dose 1 time. If still negative, do not use. <span class="rdroute">Treatment</span> 50100 g as 1520% solution over 90 min to several hours<br/><span class="rdage">Child:</span> <span class="rdroute">IV Test Dose</span> 200 mg/kg (max: 12.5 g) over 35 min <span class="rdroute">Positive Response</span> Urine flow of 1 mL/kg/h for 12 h <span class="rdroute">Maintenance</span> 0.250.5 g/kg q46 h<br/><br/><span class="indicationtitle">Edema, Ascites</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100 g as a 1020% solution over 26 h<br/><br/><span class="indicationtitle">Elevated IOP or ICP</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.52 mg/kg as a 1525% solution over 3060 min<br/><br/><span class="indicationtitle">Acute Chemical Toxicity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100200 g depending on urine output<br/><br/><span class="indicationtitle">Measurement of GFR</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100 mL of 20% solution diluted with 180 mL NaCl injection infused at a rate of 20 mL/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 						Note: Verify correct IV concentration and rate of infusion for administration to infants, children with physician. 					</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give a single dose over 3090 min. Oliguria: A test dose is given to patients with marked oliguria to check adequacy
                  of kidney function. Response is considered satisfactory if urine flow of at least 3050 mL/h is produced over 23
                  h after drug administration; then rate is adjusted to maintain urine flow at 3050 mL/h with a single dose usually being
                  infused over <img src="../images/special/greaterorequal.gif"/>90 min. Concentrations higher than 15% have a greater tendency
                  to crystallize. Use an administration set with an in-line IV filter when infusing concentrations of 15% or above.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Imipenem-cilastatin.</b> <span class="incompattype">Y-site:</span> <b>Cefepime,</b> <b>doxorubicin liposome,</b> <b>filgrastim.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed. Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, tremor, convulsions, dizziness, transient muscle rigidity. <span class="typehead">CV:</span> Edema, CHF, angina-like pain, hypotension, hypertension, thrombophlebitis. <span class="typehead">Eye:</span> Blurred vision. <span class="typehead">GI:</span> Dry mouth, nausea, vomiting. <span class="typehead">Urogenital:</span> Marked diuresis, urinary retention, nephrosis, uricosuria. <span class="typehead">Metabolic:</span> <span class="speceff-common">Fluid and electrolyte imbalance,</span> especially <span class="speceff-life">hyponatremia</span>; dehydration, acidosis. <span class="typehead">Other:</span> With extravasation (local edema, skin necrosis; chills, fever, allergic reactions). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increases urinary excretion of <b>lithium,</b> <span class="classification">salicylates</span>, <span class="classification">barbiturates</span>, <b>imipramine,</b> <b>potassium.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 13 h diuresis; 3060 min IOP; 15 min ICP. <span class="typehead">Duration:</span> 46 h IOP; 38 h ICP. <span class="typehead">Distribution:</span> Confined to extracellular space; does not cross bloodbrain barrier except with very high plasma levels in the presence
      of acidosis. <span class="typehead">Metabolism:</span> Small quantity metabolized to glycogen in liver. <span class="typehead">Elimination:</span> Rapidly excreted by kidneys. <span class="typehead">Half-Life:</span> 100 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Take care to avoid extravasation. Observe injection site for signs of inflammation or edema.</li>
<li>Lab tests: Monitor closely serum and urine electrolytes and kidney function during therapy.</li>
<li>Measure I&amp;O accurately and record to achieve proper fluid balance.</li>
<li>Monitor vital signs closely. Report significant changes in BP and signs of CHF.</li>
<li>Monitor for possible indications of fluid and electrolyte imbalance (e.g., thirst, muscle cramps or weakness, paresthesias,
            and signs of CHF).
         </li>
<li>Be alert to the possibility that a rebound increase in ICP sometimes occurs about 12 h after drug administration. Patient
            may complain of headache or confusion.
         </li>
<li>Take accurate daily weight.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following: Thirst, muscle cramps or weakness, paresthesia, dyspnea, or headache.</li>
<li>Family members should immediately report any evidence of confusion.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>